Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Morbi mattis ipsum sem
$33.00Add to cartin gravida dolor venenatis vestibulum. Aenean laoreet, nisi in bibendum dictum, purus libero accumsan enim, id vehicula enim metus vitae ipsum. Maecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat. Quisque ultricies ornare lacus, eu sagittis urna euismod ac. Nulla rhoncus ultrices ligula, id maximus ligula ultricies non.
-
Quick View
Phasellus molestie id mi sit amet
$66.00Add to cartMorbi mattis ipsum sem, in gravida dolor venenatis vestibulum. Aenean laoreet, nisi in bibendum dictum, purus libero accumsan enim, id vehicula enim metus vitae ipsum. Maecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat.
-
Quick View
Cras viverra rhoncus metu
$77.00Add to cartAenean ut commodo justo. Fusce accumsan erat ut purus mollis, quis fermentum magna luctus. Morbi pulvinar augue lorem, quis molestie ipsum dictum non. Donec malesuada fermentum ex non hendrerit. Sed tempor viverra arcu a ultrices. Suspendisse non malesuada massa. Praesent imperdiet rhoncus nunc, vel fringilla enim lacinia quis
-
Quick View
Quisque mi est, blandit sed maximus
Original price was: $63.00.$57.00Current price is: $57.00.Add to cartDuis feugiat sapien et augue dignissim porta. Nullam magna velit, laoreet porta vestibulum nec, auctor sed dui. Integer ac sodales enim. Quisque magna est, mollis euismod nibh in, elementum congue orci. Cras viverra, elit vitae iaculis efficitur, turpis urna sodales eros, vel finibus lacus elit sit amet dolor. Praesent at erat in purus pretium laoreet.
Reviews
There are no reviews yet.